Pharmaceuticals & Therapeutics

Biotech firm Sensorion drops one gene therapy to fast-track another, aiming to cure GJB2-related hearing loss, the leading cause of genetic deafness.

A popular wellness gummy is at the center of a scam epidemic. But is the product the problem, or a vast network of digital counterfeiters? We investigate.

A new partnership in regenerative medicine aims to capitalize on Florida's progressive laws. But does it signal a new era of healthspan or a risky medical frontier?

A partial settlement for California American Water's rates offers a preview of a national dilemma: how to pay for vital upgrades without overburdening consumers.

A new biologic, Nucala, gains Health Canada approval for a specific type of COPD, offering hope for patients and a new strategic frontier for GSK.

A silent disease affects 54 million Americans and is set to cost $95 billion by 2030. Now, 33 states are taking action against the osteoporosis epidemic.

A survey reveals 75% of lab researchers prioritize peptide quality over price, a clear signal against the backdrop of a scientific reproducibility crisis.

Duracell's unprecedented move to print Lionel Messi's tattoos on its batteries is more than marketing; it's a play to redefine the humble battery.

A market poised for 31% annual growth signals a new era for Alcohol-associated Liver Disease. As pharma chases a cure, a new class of drugs emerges.

A new partnership brings advanced embryo screening to the Pacific, promising healthier babies while igniting a global race and fierce ethical debates.

A new partnership between Biocartis and City of Hope seeks to transform pancreatic cancer outcomes by pairing breakthrough biomarkers with rapid diagnostic technology.

A Phase 1 trial launch is more than a milestone; it's a look at the future of pharma, where AI-driven speed and strategic global partnerships converge.

A new fellowship award spotlights how chronic stress rewrites our immune system, pointing to a future where we might reverse a key driver of aging.

A major water facility upgrade in Sydney reveals a strategic blueprint for urban growth, where advanced technology isn't just a feature but the foundation.

The genomics firm is unveiling two technologies aimed at slashing errors and automating key steps in DNA sequencing, a move that could reshape lab economics.

Matisse Pharmaceuticals' new sepsis drug just got a major boost from the FDA. But the real story is the invisible infrastructure—both biological and regulatory—it aims to master.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

An Alpharetta firm's milestone isn't just about shingles; it's a strategic play challenging the costly replacement model with sustainable, life-extending tech.

Consumers demand eco-friendly cleaners but fear they don't work. A new brand, backed by a 74-year legacy, claims its enzyme-based science can finally deliver.

EVERSANA poaches Takeda's Jen Norton to lead a new tech-first unit, signaling a high-stakes bid to dominate the complex life sciences access market.